Epidemic Keratoconjunctivitis (EKC) - Epidemiology Forecast-2032

This ‘Epidemic keratoconjunctivitis (EKC) - Epidemiology Forecast-2032' report delivers an in-depth understanding of the EKC, historical and forecasted epidemiology as well as the EKC trends in the United States, EU-5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Epidemic keratoconjunctivitis (EKC) Disease Understanding

Keratoconjunctivitis is when the patient has both keratitis and conjunctivitis simultaneously. Keratitis is inflammation of the cornea, the clear dome covering the iris and the pupil. Conjunctivitis is inflammation of the conjunctiva.

Epidemic keratoconjunctivitis (EKC) is a highly contagious viral conjunctivitis. It is caused by a group of viruses known as adenoviruses that, in addition to ocular surface infections, are responsible for causing infectious diseases of the gastrointestinal tract and respiratory system illnesses such as the common cold virus. EKC has a long incubation period and is highly contagious, leading to large outbreaks worldwide. It easily spreads where people are in close quarters, like schools, hospitals, and even doctors' offices.

The disease pathology includes the inflammation of the conjunctiva (conjunctivitis) and the cornea (keratitis). Two dilemmas are associated with this disease, first is that the virus in the early stage of incubation is asymptomatic, which leads to easy direct spread to other humans in contact; second, to date, no treatment exists with approved effect against EKC.

The adenovirus pathogen causes EKC. Adenoviral conjunctivitis is the most common cause of red-eye in the world. A study at the Wills Eye Hospital emergency room found a 62% prevalence of adenoviral conjunctivitis amongst all patients presenting with a clinical diagnosis of infectious conjunctivitis, while various other studies have demonstrated a prevalence of between 15% and 70% of all conjunctivitis worldwide.

Epidemic keratoconjunctivitis Epidemiology Perspective

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Incident Cases of Viral conjunctivitis, Total Adenovirus D-specific Incident Cases, Total Incident Cases of Epidemic keratoconjunctivitis (EKC), and Total Diagnosed Incident Cases of Epidemic keratoconjunctivitis (EKC) scenario in the 7MM covering the United States, EU-5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2019 to 2032.

EKC Detailed Epidemiology Segmentation

• In 2021, the total incident cases of EKC in the 7MM were found to be 1,820,868. These cases are expected to go down during the study period 2019-2032.
• The highest number of cases for EKC was recorded in Japan in 2021 with a total count of 999,087 cases.
• There were 7,339,945 cases of viral conjunctivitis in the 7MM in 2021. This number of viral conjunctivitis cases is anticipated to increase during the study period.
• There were a total of 597,035 diagnosed cases of EKC in the 7MM in 2021. This total number of diagnosed cases of EKC in the 7MM is anticipated to increase during the study period.
• Japan had the highest number of diagnosed EKC cases (501,522 cases) whereas there were 58,033 diagnosed cases of EKC in the United States in 2021.

Scope of the Report

• The report covers the descriptive overview of EKC, explaining its causes, symptoms, pathophysiology, and genetic basis.
• The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU-5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
• The report assesses the disease risk and burden and highlights the unmet needs of Epidemic keratoconjunctivitis.
• The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
• The report provides the segmentation of the disease epidemiology for 7MM by Total Incident Cases of Viral conjunctivitis, Total Adenovirus D-specific Incident Cases, Total Incident Cases of Epidemic keratoconjunctivitis (EKC), and Total Diagnosed Incident Cases of Epidemic keratoconjunctivitis (EKC).

Report Highlights

• 11-Year Forecast of EKC
• 7MM Coverage
• Total Incident Cases of Viral conjunctivitis
• Total Adenovirus D-specific Incident Cases
• Total Incident Cases of Epidemic keratoconjunctivitis (EKC)
• Total Diagnosed Incident Cases of Epidemic keratoconjunctivitis (EKC)

Key Questions Answered

• What are the disease risk, and burden of EKC?
• What is the historical EKC patient pool in the United States, EU-5 (Germany, France, Italy, Spain, and the UK), and Japan?
• What would be the forecasted patient pool of EKC at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to EKC?
• Out of the above-mentioned countries, which country would have the highest prevalent population of EKC during the forecast period (2022-2032)?
• At what CAGR the population is expected to grow across the 7MM during the forecast period (2022-2032)?

Reasons to Buy

The Epidemic Keratoconjunctivitis (EKC) report will allow the user to -

• Develop business strategies by understanding the trends shaping and driving the 7MM EKC epidemiology forecast.
• The EKC epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
• The EKC epidemiology model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 11-year forecast period using reputable sources.

Key Assessments

• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Geographies Covered

• The United States
• EU-5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2019-2032